Dechra Veterinary Products has announced that Sporimune (ciclosporin), its treatment for atopic dermatitis in dogs, has now been licensed for the symptomatic treatment of chronic allergic dermatitis in cats.

Sporimune is the first ciclosporin oral solution to be licensed for use in both cats and dogs.

In cats with allergic dermatitis, ciclosporin has proved to be an effective alternative to prednisolone¹ Dechra says it has a long-term safety record for chronic treatment of canine atopic dermatitis and remains one of the most important tools within a multi-modal strategy.

Sporimune is available with two dosing syringes per bottle – one for cats and one for dogs – that are graduated in body weight and ml. 

There are three bottle sizes to allow for flexibility in dispensing and broached bottles last six months. 

Dechra Brand Manager Claire Morgan said: "We are delighted to be able to introduce this popular and effective treatment for cats.

"Allergic skin disease can be challenging to diagnose and manage effectively for both owners and vets, with around 20 per cent of all small animal consultations involving skin conditions.

"Sporimune is a key component of a multi-modal approach involving guidance on allergen and flare factor avoidance and improving skin and coat hygiene to minimise clinical signs and the effects on quality of life for both animal and owner."

Reference

1. Palmeiro, B.S. (2013) Cyclosporine in Veterinary Dermatology, Vet Clin Small Anim 43, 153-171

PS: Whilst you're here, take a moment to see our latest job opportunities for vet nurses.